VANDERBILT HEALTH | Specialty Pharmacy

Identifying Inflammatory Bowel Disease Specialty Pharmacy Measures Using a Modified Delphi Method

Scan for full results and interactive details!

Autumn D. Zuckerman, PharmD, BCPS, CSP, Karen Thomas, PharmD, PhD, MBA, Shubha Bhat, PharmD, David Choi, PharmD, Dana Simonson, PharmD, BCPS, Jerry St. James, PharmD, MBA, Martha Stutsky, PharmD, BCPS, Dana Harman, PharmD, MBA, CSP, Andrew Wash, PharmD, PhD, Miranda Murray, PharmD, CSP, Jessica Fann, PharmD, Josh DeClercq, MS *See QR code for affiliations

Acknowledgements *(see QR code for details):*

We would like to acknowledge the entire study team who provided guidance on the study protocol, participated in the environmental scan, completed the survey rounds, and voted on the final measures, as well as the 142 expert panelists who participated in the study.

Purpose

Gap

Standardized, reportable measures for specialty pharmacies are needed to enable benchmarking and improve patient care and specialty medication management.

Aim

To determine consensus among specialty pharmacy stakeholders on important, actionable, and feasible measures for specialty pharmacies managing specialty medications in patients with Inflammatory Bowel Disease (IBD).

Methods

Figure 1. Modified Delphi Methodology



Definitions

Important: Meaningful for patient care

Actionable: Can be used to make treatment and clinical decisions based on result

Feasible: Level of ease/ability for a specialty pharmacy to collect and report

CONCLUSIONS

- Six core IBD measures and 6 reach measures were identified using the modified Delphi method to be important, actionable, and feasible by specialty stakeholders.
- Implementing the consensus measures among specialty pharmacies and within stakeholder reporting guidelines is key to improving consistency in reporting and patient care.

Results

Figure 2. Response Rates



Each round had at least 1 response from each expert panelist type

Prescribing providers had the highest representation in each round, followed by specialty-affiliated experts (IBD pharmacists, specialty pharmacy leadership/analysis, and technicians).

Figure 3. Scoring Results



*A "limiting score" was calculated as the lowest of either important or actionable scores

Round 1 Inclusion criteria
Limiting: mean and median score ≥7.5
Feasibility: at least 90% of experts scored ≥4

Round 2 Inclusion criteria
Limiting: median score ≥7
Feasibility: at least 80% of experts scored ≥4

Final Measures

Core Measures

Should be collected and reported by all specialty pharmacies without exception

- Pre-initiation Safety Screening
- Adherence
- Serious Adverse Events
- Pharmacist Interventions
- Post-initiation Safety Monitoring
- Medication Persistence

Reach Measures

Important and usable, but not yet essential for specialty pharmacies to collect and report

- Symptom Control
- Discontinuation Reason
- Recent Steroid Use
- Treat-to-Target Goal Status
- Unplanned Healthcare Utilization
- Continuity of Care Evaluation